Cabotegravir

ArtNr	HY-15592-25mg
Hersteller	MedChem Express
CAS-Nr.	1051375-10-0
Menge	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.91
Citations	[1]Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12.\|[2]Zhou T, et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials. 2018 Jan;151:53-65.\|[3]Yoshinaga T, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015 Jan;59(1):397-406.\|[4]Andrews CD, et al. Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS. 2017 Feb 20;31(4):461-467.
Smiles	FC1=C(CNC(C2=CN3C(C(N([C@@H](C)CO4)[C@@]4([H])C3)=O)=C(O)C2=O)=O)C=CC(F)=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GSK-1265744,S/GSK1265744
Similar products	1051375-10-0
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	HIV; HIV Integrase; OAT
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	405.35
Product Description	Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS[1][2].
Manufacturer - Research Area	Infection
Solubility	DMSO: 14 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Anti-infection; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-15592-25mg-safety-datasheet.pdf